The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,908.00
Bid: 4,906.00
Ask: 4,908.00
Change: -4.00 (-0.08%)
Spread: 2.00 (0.041%)
Open: 4,906.00
High: 4,910.00
Low: 4,888.00
Prev. Close: 4,912.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

12 Feb 2008 07:00

Intertek Group PLC12 February 2008 Stock Exchange Release 12 February 2008, 7am London, UK Intertek acquires Bioclin, an Irish pharmaceutical testing laboratory. Intertek Group plc (Intertek), the leading international provider of quality andsafety services to a wide range of industries, announces the acquisition ofBioclin Research Laboratories Ltd (Bioclin), a pharmaceutical testing laboratoryin Ireland. Intertek purchased Bioclin from its shareholders Mary Burke, Brian McKenna andEnterprise Ireland for an initial cash consideration of EUR 3.2 million (GBP 2.4million). A further payment of up to EUR 1.0 million (GBP 0.7 million) ispayable in April 2009, dependent on Bioclin's 2008 financial performance. Bioclin provides product quality testing and bio-analytical services topharmaceutical, medical device and biotechnology companies locally andinternationally. The laboratory holds Good Laboratory Practice ("GLP") and GoodManufacturing Practice ("cGMP") certifications. Ireland is a key European centrefor pharmaceutical manufacturing, and increasingly R&D, with many of the world'stop-selling drugs being produced there. Bioclin joins Intertek's existing specialist pharmaceutical labs in the UK, US,India, and Australia, further extending Intertek's global support topharmaceutical R&D and manufacturing in key regions. Located in Athlone, centralIreland, Bioclin has 20 employees and will form part of Intertek's AnalyticalServices division1. Wolfhart Hauser, Chief Executive Officer of Intertek, commented: "Bioclin is a great complement to Intertek's growing global pharmaceuticalanalytical services business and increases our worldwide support network tocustomers in the sector. We also further strengthen our position to capture thegrowth opportunities that lie within the trend for increased outsourcing of R&Dsupport and analytical services in pharmaceutical development". -ends- Contacts Aston Swift / Sarah Ogilvie IntertekTelephone: +44 (0) 20 7396 3400aston.swift@intertek.com / sarah.ogilvie@intertek.com Richard Mountain / Sophie Kernon, Financial DynamicsTelephone: +44 (0) 20 7269 7121richard.mountain@fd.com / sophie.kernon@fd.com Notes to Editors 1. From 1 January 2008, Intertek's Analytical Services, previously part of theGroup's Oil Chemical & Agri division, became a standalone division. For furtherdetails of this and the surrounding divisional re-organisation, refer toIntertek's stock exchange announcement of 11 December 2007. ABOUT INTERTEKIntertek (LSE: ITRK) is the leading international provider of quality and safety services to a wide range of global and local industries. Partnership with Intertek brings increased value to customers' products and processes, ultimately supporting their success in the global market place. Intertek has the experience, expertise, resources and global reach to support its customers through its extensive network of laboratories and offices, with over 20,000 people in more than 100 countries around the world. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement
23rd May 20221:00 pmRNSBlock listing Interim Review
4th Apr 20223:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
18th Mar 20229:00 amRNSAnnual Financial Report
14th Mar 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.